Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for NKX019 (CAR NK Therapy) in Primary Membranous Nephropathy. The expected timing is based on the latest available company guidance and may change.
08/10/26:- Ntrust trials enroll primary membranous nephropathy; initial data expected in 2026.
Verification
Confirm timing and program details against the company announcement or filing.